Eating Disorder
Conditions
Keywords
autoantibodies (autoAc) circulating, neuropeptides (Ghrelin, l'α-MSH), potential digestive origin
Brief summary
This study should lead to the validation of the concept of the autoAc directed against the neuropeptides involved in food intake regulation.
Detailed description
Eating disorders are a public health issue. It has been recently reported the importance of immune system modifications in eating disorders physiopathology, involving autoantibodies directed against neuropeptides regulating food intake. A recent study of laboratory INSERM 1073 showed the existence of an intestinal bacterial protein exhibiting structural similarities with α-MSH: ClpB. The autoAc directed against the latter also react with α-MSH because of these similarity of structures, thus leading to a potential digestive origin of these autoAc. To consolidate this new etiopathogenic assumption, a large clinical study is necessary with analysis of patients autoAc profiles. a monocentric study with inclusion of 240 patients over 2 years and 80 healthy volunteers is proposed. This study should lead to the validation of the concept of the autoAc directed against the neuropeptides involved in food intake regulation. Nutritional modulations (probiotic, amino-acid…) could constitute an interesting therapeutic perspective in the future.
Interventions
OTHEREvaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) controlling involved in food intake regulation
blood samples (12ml) and stool samples (30g) collections
Sponsors
University Hospital, Rouen
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Intervention model description
Eating disorders compared to healthy volonteers
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
Patients with eating disorders 1. 18 Years and older 2. first clinical visit in nutrition department of CHU de Rouen for eating disorders 3. anorexia nervosa, hyperphagia or bulimia according to the classification DSM-V 4. social security Affiliation 5. Patient who signed the MEC approved informed consent Volunteers 1. 18 Years to 60 Years 2. body mass index ≥ 18,5 kg/m2 and ≤ 24,9 kg/m2 3. negative SCOFF test 4. No active and history of eating disorders 5. social security Affiliation 6. volunteer who signed the MEC approved informed consent
Exclusion criteria
Patients with eating disorders 1. No anorexia nervosa, hyperphagia or bulimia according to the classification DSM-V 2. Adults under legal protection or under safeguard of justice or administrative decision 3. Pregnancy Volunteers 1. Active or history of eating disorder 2. Adults under legal protection or under safeguard of justice or administrative decision 3. Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) involved in food intake regulation among patients with eating disorders | 1 week | blood samples collections |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Scale for determination factors associated with eating disorders | 1 week | A global scale will evaluate : * socio demographic factors * somatic and psychiatric comorbidities * addictions * personal and family antecedents * major events |
| statute in autoantibody and behavioral characteristics of the eating disorder | 1 week | quality of life and the psychological state of the patients tests |
| Evaluation of the rate of the autoantibodies directed against bacterial peptide, ClpB among patients presenting with eating disorders | 1 week | stoll samples collections |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORNajate EL MACHKOURI ACHAMRAH, MD, PhD
University Hospital, Rouen
Outcome results
None listed